Literature DB >> 26582883

Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children.

Ruth A Karron1, Jocelyn San Mateo1, Bhagvanji Thumar1, Anne Schaap-Nutt2, Ursula J Buchholz2, Alexander C Schmidt2, Emmalene J Bartlett2, Brian R Murphy2, Peter L Collins2.   

Abstract

We conducted a phase I clinical trial (clinicaltrials.gov identifier, NCT00641017) of the experimental live-attenuated human parainfluenza virus type 1 (HPIV-1) vaccine rHPIV-1/84/del 170/942A sequentially in 3 groups: adults, HPIV-1-seropositive children, and HPIV-1-seronegative children, the target population for vaccination. rHPIV-1/84/del 170/942A was appropriately restricted in replication in adults and HPIV-1-seropositive children but was overattenuated (ie, insufficiently infectious and immunogenic) for HPIV-1-seronegative children.
© The Author 2014. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HPIV-1 vaccine; children; lower respiratory tract illness

Mesh：

Substances：

Year:  2014        PMID： 26582883      PMCID： PMC4681387          DOI： 10.1093/jpids/piu104

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN： 2048-7193            Impact factor:   3.164


  11 in total

1.  An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials.

Authors:  Sonja R Surman; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal:  J Virol Methods       Date:  2007-01-08       Impact factor: 2.014

Review 2.  Progress in the development of human parainfluenza virus vaccines.

Authors:  Alexander C Schmidt; Anne Schaap-Nutt; Emmalene J Bartlett; Henrick Schomacker; Jim Boonyaratanakornkit; Ruth A Karron; Peter L Collins
Journal:  Expert Rev Respir Med       Date:  2011-08       Impact factor: 3.772

3.  Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old.

Authors:  G Reed; P H Jewett; J Thompson; S Tollefson; P F Wright
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

4.  A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children.

Authors:  R A Karron; P F Wright; S L Hall; M Makhene; J Thompson; B A Burns; S Tollefson; M C Steinhoff; M H Wilson; D O Harris
Journal:  J Infect Dis       Date:  1995-05       Impact factor: 5.226

5.  Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants.

Authors:  R A Karron; M Makhene; K Gay; M H Wilson; M L Clements; B R Murphy
Journal:  Pediatr Infect Dis J       Date:  1996-08       Impact factor: 2.129

6.  Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization.

Authors:  Geoffrey A Weinberg; Caroline B Hall; Marika K Iwane; Katherine A Poehling; Kathryn M Edwards; Marie R Griffin; Mary Allen Staat; Aaron T Curns; Dean D Erdman; Peter G Szilagyi
Journal:  J Pediatr       Date:  2009-01-21       Impact factor: 4.406

7.  Croup: an 11-year study in a pediatric practice.

Authors:  F W Denny; T F Murphy; W A Clyde; A M Collier; F W Henderson
Journal:  Pediatrics       Date:  1983-06       Impact factor: 7.124

8.  Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.

Authors:  Ruth A Karron; Bhagvanji Thumar; Elizabeth Schappell; Sonja Surman; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  Vaccine       Date:  2011-12-14       Impact factor: 3.641

9.  Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.

Authors:  Emmalene J Bartlett; Adam Castaño; Sonja R Surman; Peter L Collins; Mario H Skiadopoulos; Brian R Murphy
Journal:  Virol J       Date:  2007-07-02       Impact factor: 4.099

10.  Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.

Authors:  Janet A Englund; Ruth A Karron; Coleen K Cunningham; Philip Larussa; Ann Melvin; Ram Yogev; Ed Handelsman; George K Siberry; Bhavanji Thumar; Elizabeth Schappell; Catherine V Bull; Helen Y Chu; Anne Schaap-Nutt; Ursula Buchholz; Peter L Collins; Alexander C Schmidt
Journal:  Vaccine       Date:  2013-10-05       Impact factor: 3.641
View more
  12 in total

1.  Parainfluenza Virus 3-Specific T Cells: Opportunity for Intervention?

Authors:  Alpana Waghmare; Janet A Englund; Michael Boeckh
Journal:  J Infect Dis       Date:  2017-07-15       Impact factor: 5.226

2.  Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.

Authors:  Xiang Liu; Bo Liang; Joan Ngwuta; Xueqiao Liu; Sonja Surman; Matthias Lingemann; Peter D Kwong; Barney S Graham; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2017-10-27       Impact factor: 5.103

Review 3.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

Review 4.  How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation.

Authors:  Alpana Waghmare; Janet A Englund; Michael Boeckh
Journal:  Blood       Date:  2016-03-11       Impact factor: 22.113

Review 5.  Vaccines for the common cold.

Authors:  Daniel Simancas-Racines; Juan Va Franco; Claudia V Guerra; Maria L Felix; Ricardo Hidalgo; Maria José Martinez-Zapata
Journal:  Cochrane Database Syst Rev       Date:  2017-05-18

6.  Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.

Authors:  Natalie Mackow; Emérito Amaro-Carambot; Bo Liang; Sonja Surman; Matthias Lingemann; Lijuan Yang; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

7.  Features of Circulating Parainfluenza Virus Required for Growth in Human Airway.

Authors:  Laura M Palermo; Manik Uppal; Lucy Skrabanek; Paul Zumbo; Soren Germer; Nora C Toussaint; Bert K Rima; Devra Huey; Stefan Niewiesk; Matteo Porotto; Anne Moscona
Journal:  MBio       Date:  2016-03-15       Impact factor: 7.867

8.  Structural Insight into the Interaction of Sendai Virus C Protein with Alix To Stimulate Viral Budding.

Authors:  Kosuke Oda; Yasuyuki Matoba; Masanori Sugiyama; Takemasa Sakaguchi
Journal:  J Virol       Date:  2021-09-09       Impact factor: 5.103

9.  Global burden of acute lower respiratory infection associated with human parainfluenza virus in children younger than 5 years for 2018: a systematic review and meta-analysis.

Authors:  Xin Wang; You Li; Maria Deloria-Knoll; Shabir A Madhi; Cheryl Cohen; Vina Lea Arguelles; Sudha Basnet; Quique Bassat; W Abdullah Brooks; Marcela Echavarria; Rodrigo A Fasce; Angela Gentile; Doli Goswami; Nusrat Homaira; Stephen R C Howie; Karen L Kotloff; Najwa Khuri-Bulos; Anand Krishnan; Marilla G Lucero; Socorro Lupisan; Maria Mathisen; Kenneth A McLean; Ainara Mira-Iglesias; Cinta Moraleda; Michiko Okamoto; Histoshi Oshitani; Katherine L O'Brien; Betty E Owor; Zeba A Rasmussen; Barbara A Rath; Vahid Salimi; Pongpun Sawatwong; J Anthony G Scott; Eric A F Simões; Viviana Sotomayor; Donald M Thea; Florette K Treurnicht; Lay-Myint Yoshida; Heather J Zar; Harry Campbell; Harish Nair
Journal:  Lancet Glob Health       Date:  2021-06-21       Impact factor: 38.927

10.  The contribution of viruses and bacteria to community-acquired pneumonia in vaccinated children: a case-control study.

Authors:  Mejbah Uddin Bhuiyan; Thomas L Snelling; Rachel West; Jurissa Lang; Tasmina Rahman; Caitlyn Granland; Camilla de Gier; Meredith L Borland; Ruth B Thornton; Lea-Ann S Kirkham; Chisha Sikazwe; Andrew C Martin; Peter C Richmond; David W Smith; Adam Jaffe; Christopher C Blyth
Journal:  Thorax       Date:  2018-10-18       Impact factor: 9.139
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.